Cassava Sciences Inc.
416 Browning Way
South San Francisco
California
94080
United States
Tel: 650-624-8200
Fax: 650-624-8222
Website: http://www.paintrials.com/
273 articles with Cassava Sciences Inc.
-
Cassava Sciences Reports Full-year 2022 Financial Results and Operating Updates
2/28/2023
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the year ended December 31, 2022, and provided operating updates.
-
Cassava Sciences Announces Patient Enrollment Update for Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease
2/8/2023
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced an update on patient enrollment for its on-going Phase 3 clinical studies of simufilam for the treatment of Alzheimer’s disease dementia.
-
Cassava Sciences reported Phase II data from its Alzheimer's candidate simufilam Tuesday. The company’s stock dropped 17% following the reveal.
-
Cassava Sciences Announces Positive Top-Line Clinical Results in Phase 2 Study Evaluating Simufilam in Alzheimer’s Disease
1/24/2023
Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced positive top-line Phase 2 results for simufilam, its oral drug candidate for Alzheimer’s disease dementia.
-
Cassava Sciences Mourns the Death of Board Member and Officer Nadav Friedmann, PhD, MD
12/20/2022
Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered.
-
Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease
12/6/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzheimer’s disease.
-
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
11/22/2022
Cassava Sciences, Inc. announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million.
-
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
11/18/2022
Cassava Sciences, Inc. announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offering.
-
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
11/7/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease.
-
Cassava Files Defamation Suit against Short Sellers Linked to Data Manipulation Allegations - Upd...
11/3/2022
Cassava filed a lawsuit in federal court against individuals linked to a Citizen's Petition filed with the FDA that raised concerns about data manipulation in a clinical study of simufilam. -
Cassava Sciences Announces Expansion of Leadership Team
10/27/2022
Cassava Sciences, Inc., a clinical-stage biotechnology company focused on Alzheimer’s disease, announced the expansion of its leadership team with the appointment of Christopher Cook as Senior Vice President and General Counsel.
-
Cassava Sciences Announces Initiation of an Open-label Extension Study
10/13/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the initiation of an open-label extension study.
-
Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference
9/8/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it has been invited to present a corporate overview at the H.C. Wainwright 24th Annual Global Investment Conference, being held in New York.
-
Cassava Sciences has been informed by the Journal of Prevention of Alzheimer's Disease that there is no evidence to support the charges, the company said Thursday.
-
No Evidence of Data Manipulation in Science Publication on Simufilam
8/18/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, was recently informed by the Journal of Prevention of Alzheimer's Disease (JPAD) that there is no convincing evidence to support allegations of data manipulation in a 2020 paper on simufilam co-authored by the Company’s personnel and its science collaborators.
-
Researchers have found that two common viruses—the varicella zoster and herpes simplex viruses—likely constitute a pathway that leads to Alzheimer's disease.
-
Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study
8/3/2022
Cassava Sciences, Inc. today announced financial results for the second quarter ended June 30, 2022, a mid-year corporate update, and interim clinical results of an open-label study with simufilam.
-
The probe will be led by investigators experienced in determining whether or not entities have defrauded consumers, investors or government agencies.
-
Cassava Sciences Responds to Media Reports
7/27/2022
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, reiterated today what it had previously disclosed in 2021, that certain government agencies had requested information from the Company.
-
Scientific Community Questions Anti-Amyloid Theory - the Basis for Seminal Alzheimer's Work
7/22/2022
The data used to support the argument that Aβ*56 is responsible for the Alzheimer’s Disease hallmark of memory loss appears to have been fabricated or heavily tampered with.